Targeting EIF2AK3 and its PI3K/AKT-mediated autophagic pathway represents a promising strategy for overcoming DDP resistance and improving therapeutic outcomes in NSCLC patients. Here, EIF2AK3 is linked to non-small cell lung carcinoma.